Search

Displaying results 1511 - 1520 of 1901 in total
  1. Drug

    Abemaciclib

    go.drugbank.com/drugs/DB12001
    ApprovedInvestigational

    On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed

  2. Drug

    Tenofovir alafenamide

    go.drugbank.com/drugs/DB09299
    ApprovedInvestigational

    [L4388,L9010] Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval on 5 November 2015.[L6271]

  3. Drug

    Garetosmab

    go.drugbank.com/drugs/DB16379
    ApprovedInvestigational

    [L63940] Garetosmab-grts was approved by the FDA on August 19, 2026 to reduce the number of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP. … [L63940] It is a fully human IgG4 monoclonal antibody that binds and neutralizes activin A, blocking activin A from activating the mutant ACVR1 receptor that, in FOP, drives the formation of heterotopic

  4. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    [A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata.

  5. Drug

    Tramadol

    go.drugbank.com/drugs/DB00193
    ApprovedInvestigational

    property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor

    Mixtures: Nra-tramadol/acetCategories: NMDA Receptor Antagonists, Serotonin Receptor Antagonists
  6. Drug

    XP12B

    go.drugbank.com/drugs/DB04928
    Investigational

    It was granted Fast Track status for this indication by the FDA in November 2004.

  7. Drug

    ALMB-0166

    go.drugbank.com/drugs/DB17937
    Investigational

    It was granted FDA orphan designation in November 2018.[L47067]

  8. Drug

    Bevacizumab

    go.drugbank.com/drugs/DB00112
    ApprovedInvestigational

    [A286054] In 2004, bevacizumab (Avastin) gained FDA approval and became the first antiangiogenic agent introduced to the market, indicated in combination with chemotherapy regimens specific to the type … gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically for intravitreal injection, which received European Commission and MHRA marketing authorization in 2024 and FDA

    Categories: VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitorsSynonyms: Bei Fa Zhu Dankang
  9. Drug

    Fenproporex

    go.drugbank.com/drugs/DB01550
    ApprovedIllicitWithdrawn

    In 2006 and 2009, the FDA issued warnings that it had been detected in diet pills sold online, and imported from foreign manufacturers. … practice, central nervous system stimulative effects are less notorious than with some other agents such as diethylpropion and mazindol. [7] In the United States fenproporex was never approved by the FDA

  10. Drug

    Viltolarsen

    go.drugbank.com/drugs/DB15005
    ApprovedInvestigational

    [A218186] Hence, viltolarsen is similar to another PMO, [eteplirsen], which gained FDA approval on September 19, 2016; however, [eteplirsen] is specific for exon 51 skipping while viltolarsen is specific … [A218176] Viltolarsen was granted accelerated FDA approval on August 12, 2020, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with viltolarsen; this approval